Alvogen certainly seems to be leaping from strength to strength these days and just returned from the CPhI in the Spanish capital Madrid last week with another prize for its already crowded trophy cabinet.
Alvogen is leaping from strength to strength these days and just returned from the world largest pharmaceutical exhibition (CPhI) held in the Spanish capital Madrid last week with another prize for its already crowded trophy cabinet. This time Alvogen won the Europe, the Middle East and Africa (EMEA) Company of the Year title at the Global Generics & Biosimilars Awards 2015, which were presented at the Palacio Municipal de Congresos in Madrid.
The Global Generics & Biosimilars Awards reward “best practice” in both sectors, while at the same time encouraging improvements in every aspect of the way business is conducted.
Every Award effectively underscores the efforts made by the global generics and biosimilars sectors to make more affordable medicines available to more people everywhere.
Alvogen was also nominated for three other awards: Overall Company of the Year, Leader of the Year (Robert Wessman) and Corporate Social Responsibility (CSR) Initiative of the Year.
“Naturally, we’re delighted to have been nominated in all those prestigious categories,” Robert Wessman, CEO and Chairman of Alvogen, commented in a jubilant mood, “and to have come home with the EMEA Company of the Year award. It’s always a great boost to get this kind of recognition, which has been won by all the hard work put in by our team. We’ve been building up our presence in the CEE region for quite some time now and Alvogen currently has offices in 21 country there.
Our largest markets in the region include Romania, Bulgaria, Russia and Hungary. We have 200 products in our global pipeline and over 500 on the market. It’s also wonderful to see the growing attention Alvogen has been attracting at the CPhI every year,” Wessman added, “ and how firmly we’ve now established ourselves on the global map.”
This year’s fun event at the Alvogen stand in Madrid was a tournament on a golf simulator, which gave contestants a chance to play on Scotland’s historical St. Andrews course, albeit in the virtual world. The purpose of this entertaining exercise was to highlight the company’s quest for strong drivers in pharma and create an informal setting for meeting new colleagues and renewing contacts.